Use of daratumumab in high risk multiple myeloma: A meta‐analysis

Daratumumab is approved for use in newly diagnosed and relapsed/refractory multiple myeloma (MM), however the patients most likely to benefit from its addition to standard anti‐myeloma therapy is unclear. This meta‐analysis included 2340 newly diagnosed MM patients (1982 with standard risk and 358 w...

Descripción completa

Detalles Bibliográficos
Autores principales: Premkumar, Vikram, Pan, Samuel, Lentzsch, Suzanne, Bhutani, Divaya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175911/
https://www.ncbi.nlm.nih.gov/pubmed/35847747
http://dx.doi.org/10.1002/jha2.47